ArticleFrontiers in pharmacology2022

The XPO1 Inhibitor KPT-8602 Ameliorates Parkinson's Disease by Inhibiting the NF-κB/NLRP3 Pathway.

Shuhan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.